Only two days after Bridgebio Pharma Inc. impressed investors with data from BBP-418 in limb-girdle muscular dystrophy type ...

Leading advances in cancer research, the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ...

Medline Inc. filed a public S1 with the SEC Oct. 28, moving the IPO first signaled in December 2024 closer to reality. The Northfield, Ill.-based medical supply distributor did not disclose the number ...

In September 2025, BioWorld recorded 230 clinical trial updates spanning phases I through III, up sharply from 95 in August, ...

Stakeholders of all stripes have wondered whether transcatheter aortic valve replacement devices could match their surgically ...

Biomarin Pharmaceutical Inc. plans to divest its pioneering gene therapy for hemophilia, Roctavian (valoctocogene ...

U.K. biotech companies raised 46% less in the third quarter (Q3) of 2025 than in the previous quarter, at £187 million ...

Trials are being conducted at three pediatric emergency departments in England of the Memed BV rapid blood test, designed to ...

Hanmi Pharmaceutical Co. Ltd. announced Oct. 27 that its glucagon-like peptide-1 receptor agonist, efpeglenatide (HM-11260C), met the co-primary endpoints in a phase III study of obese adults without ...

Doctors and device makers are habituated to the notion that more devices equal better outcomes, but one presenter at this ...

Although Argenica Therapeutics Ltd.’s stroke drug, ARG-007, saw mixed results in top-line phase II data, new data in ...

Penumbra Inc.’s 'resoundingly positive' results from its STORM-PE trial could see current guidelines for anticoagulant use in ...